Christopher Kim
Chairman and CMO at Apimeds Pharmaceuticals US Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 2 years
- Director since
- 2025
2 years of board service in total across 1 board, counting each seat separately. Longest: Apimeds Pharmaceuticals US Inc., 1 year.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 16, 2025 | Apimeds Pharmaceuticals US Inc. | Grant or award | +250,000 | — | — |
| May 14, 2025 | Apimeds Pharmaceuticals US Inc. | Open-market purchase | +7,730 | $1.86 | $14,378 |
| May 13, 2025 | Apimeds Pharmaceuticals US Inc. | Open-market purchase | +19,770 | $1.82 | $35,981 |
Questions about Christopher Kim
What boards is Christopher Kim on?
Christopher Kim sits on the board of Apimeds Pharmaceuticals US Inc.
How long has Christopher Kim served on boards?
Our records show at least 2 years of board service across 1 board, the earliest from 2025.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.